PMC5364931_01
Axial T2-weighted (A) and sagittal T1-weighted (B) MR images show the left frontal intra-axial mass lesion that was hyperintense on T2-(A) and hypointense on T1-(B) weighted images. The lesion shows intense and homogeneous enhancement on postcontrast T1-weighted (C) image. MR images (A-C) reveal the prominent peritumoral vasogenic edema. T1-weighted images show no contrast enhancement was detected in the operation area (D). MR: magnetic resonance.
nmccrj-2-031-g001.jpg
PMC5364931_01_nmccrj-2-031-g001.jpg
F1
T1-weighted (Fig. 1B) images. The T1-weighted imaging following gadolinium injection demonstrated the prominent and homogeneous enhancement of the lesion (Fig. 1C). There was a prominent peritumoral vasogenic edema. Post-operative MRI examination showed total removal of tumor (Fig. 1D).
A: Alveolar soft part sarcoma showing alveolar nesting pattern with tumor cells containing abundant eosinophilic cytoplasm and discohesive nature (H&E, x40), B: There are histochemically PAS-positive and diastase-resistant rod-shaped multiple crystalline materials in the cytoplasm of some tumor cells (dPAS, x400), C: Histochemically reticulin (silver) framework surrounding the tumor nests (Reticulin, x400), D: Tumor cells showing focal immunoreactivity with GFAP (x400), E: Tumor cells with no immunoreactivity with S100 protein (x400), F: Several tumor cells showing nuclear immunoreactivity with TFE3 (x400). PAS: periodic acid schiff, dPAS: distaste periodic acid schiff, GFAP: glial fibrillary acidic protein, TFE3: transcription factor E3.
nmccrj-2-031-g002.jpg
PMC5364931_01_nmccrj-2-031-g002.jpg
F2
These findings revealed alveolar soft sarcoma (Fig. 2A-F).
The lesion shows intense and homogeneous enhancement on postcontrast T1-weighted image (A) and gross-total removal of tumor (B).
nmccrj-2-031-g003.jpg
PMC5364931_01_nmccrj-2-031-g003.jpg
F3
The T1-weighted imaging following gadolinium injection demonstrated the prominent and homogeneous enhancement of the recurrent lesion (Fig. 3A). There was no contrast enhancement at the postop control MRI (Fig. 3B).